1.GBD Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1545–1602.
2.Hayes, JF, Miles, J, Walters, K, King, M, Osborn, DPJ (2015) A systematic review and meta-analysis of premature mortality in bipolar affective disorder. Acta Psychiatr Scand 131, 417–425.
3.Brown, S, Kim, M, Mitchell, C, Inskip, H (2010) Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 196, 116–121.
4.Lawrence, D, Hancock, KJ, Kisely, S (2013) The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: Retrospective analysis of population based registers. BMJ 346, f2539.
5.Saha, S, Chant, D, McGrath, J (2007) A systematic review of mortality in schizophrenia. Arch Gen Psychiatry 64, 1123.
6.Leucht, S, Burkard, T, Henderson, J, Maj, M, Sartorius, N (2007) Physical illness and schizophrenia: A review of the literature. Acta Psychiatr Scand 116, 317–333.
7.Millier, A, Schmidt, U, Angermeyer, MC, et al. (2014) Humanistic burden in schizophrenia: A literature review. J Psychiatr Res Pergamon 54, 85–93.
8.Wahlbeck, K, Westman, J, Nordentoft, M, Gissler, M, Laursen, TM (2011) Outcomes of Nordic mental health systems: Life expectancy of patients with mental disorders. Br J Psychiatry 199, 453–458.
9.Farrelly, S, Clement, S, Gabbidon, J, et al. (2014) Anticipated and experienced discrimination amongst people with schizophrenia, bipolar disorder and major depressive disorder: A cross sectional study. BMC Psychiatry BioMed Central 14, 157.
10.Thornicroft, G, Brohan, E, Rose, D, et al. (2009) Global pattern of experienced and anticipated discrimination against people with schizophrenia: A cross-sectional survey. Lancet 373, 408–415.
11.Karidi, MV, Vassilopoulou, D, Savvidou, E, et al. (2015) Bipolar disorder and self-stigma: A comparison with schizophrenia. J Affect Disord 184, 209–215.
12.Pattyn, E, Verhaeghe, M, Sercu, C, Bracke, P (2013) Medicalizing versus psychologizing mental illness: What are the implications for help seeking and stigma? A general population study. Soc Psychiatry Psychiatr Epidemiol 48, 1637–1645.
13.Foruzandeh, N, Parvin, N (2013) Occupational therapy for inpatients with chronic schizophrenia: A pilot randomized controlled trial. Japan J Nurs Sci 10, 136–141.
14.Killackey, EJ, Jackson, HJ, Gleeson, J, Hickie, IB, Mcgorry, PD (2006) Exciting career opportunity beckons! Early intervention and vocational rehabilitation in first-episode psychosis: Employing cautious optimism. Aust New Zeal J Psychiatry 40, 951-62.
15.Szkultecka-Dębek, M, Miernik, K, Stelmachowski, J, et al. (2016) Schizophrenia causes significant burden to patients’ and caregivers’ lives. Psychiatr Danub 28, 104–110.
16.Wilens, TE, Biederman, J, Forkner, P, et al. (2003) Patterns of comorbidity and dysfunction in clinically referred preschool and school-age children with bipolar disorder. J Child Adolesc Psychopharmacol 13, 495–505.
17.Carlborg, A, Ferntoft, L, Thuresson, M, Bodegard, J (2015) Population study of disease burden, management, and treatment of bipolar disorder in Sweden: A retrospective observational registry study. Bipolar Disord 17, 76–85.
18.Marwaha, S, Durrani, A, Singh, S (2013) Employment outcomes in people with bipolar disorder: A systematic review. Acta Psychiatr Scand 128, 179–193.
19.Judd, LL, Schettler, PJ, Solomon, DA, et al. (2008) Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord 108, 49–58.
20.Chong, HY, Teoh, SL, Wu, DB et al. (2016) Global economic burden of schizophrenia: A systematic review. Neuropsychiatr Dis Treat 12, 357–373.
21.McCrone, P, Dhanasiri, S, Patel, A, Knapp, M, Lawton-Smith, S (2008) Paying the price: The cost of mental health care in England to 2026 [cited February 12, 2016]. http://www.kingsfund.org.uk/sites/files/kf/Paying-the-Price-the-cost-of-mental-health-care-England-2026-McCrone-Dhanasiri-Patel-Knapp-Lawton-Smith-Kings-Fund-May-2008_0.pdf.s
22.Kennedy, JL, Altar, CA, Taylor, DL, Degtiar, I, Hornberger, JC (2014) The social and economic burden of treatment-resistant schizophrenia. Int Clin Psychopharmacol 29, 63–76.
23.McDonagh, MS, Dana, T, Selph, S, et al. (2017) Treatments for Schizophrenia in Adults: A Systematic Review. Rockville, MD: Agency for Healthcare Research and Quality
24.Fountoulakis, KN, Vieta, E (2008) Treatment of bipolar disorder: A systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 11, 999–1029.
25.Pfammatter, M, Junghan, UM, Brenner, HD (2006) Efficacy of psychological therapy in schizophrenia: Conclusions from meta-analyses. Schizophr Bull 32(Suppl 1), S64–S80.
26.Swartz, HA, Swanson, J (2014) Psychotherapy for bipolar disorder in adults: A review of the evidence. Focus (Am Psychiatr Publ) 12, 251–266.
29.Reilly, S, Planner, C, Hann, M, et al. (2012) The role of primary care in service provision for people with severe mental illness in the United Kingdom. Baradaran HR, editor. PLoS One 7, e36468.
30.Amos, A (2012) Assessing the cost of early intervention in psychosis: A systematic review. Aust New Zeal J Psychiatry 46, 719–734.
31.Desmedt, M, Vertriest, S, Hellings, J, et al. (2016) Economic impact of integrated care models for patients with chronic diseases: A systematic review. Value Health 19, 892–902.
32.Abdul Pari, AA, Simon, J, Wolstenholme, J, Geddes, JR, Goodwin, GM (2014) Economic evaluations in bipolar disorder: A systematic review and critical appraisal. Bipolar Disord 16, 557–582.
33.Shields, G, Davies, L, Buck, D, Elvidge, J, Hayhurst, K (2017) A systematic review of cost-effectiveness evaluations of psychological therapies for schizophrenia and bipolar disorder. PROSPERO CRD42017056579. [cited March 3, 2018]. http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017056579.
35.Husereau, D, Drummond, M, Petrou, S, et al. (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ 346, f1049.
38.Haddock, G, Barrowclough, C, Tarrier, N, et al. (2003) Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. Br J Psychiatry 183, 418–426.
39.Barton, GR, Hodgekins, J, Mugford, M, et al. (2009) Cognitive behaviour therapy for improving social recovery in psychosis: Cost-effectiveness analysis. Schizophr Res 112, 158–163.
40.McCrone, P, Craig, TKJ, Power, P, Garety, PA (2010) Cost-effectiveness of an early intervention service for people with psychosis. Br J Psychiatry 196, 377–382.
41.Patel, A, Knapp, M, Romeo, R, et al. (2010) Cognitive remediation therapy in schizophrenia: Cost-effectiveness analysis. Schizophr Res 120, 217–224.
42.van der Gaag, M, Stant, AD, Wolters, KJK, Buskens, E, Wiersma, D (2011) Cognitive-behavioural therapy for persistent and recurrent psychosis in people with schizophrenia-spectrum disorder: Cost-effectiveness analysis. Br J Psychiatry 198, 59–65.
43.Crawford, M, Killaspy, H, Barnes, T, et al. (2012) Group art therapy as an adjunctive treatment for people with schizophrenia: A randomised controlled trial (MATISSE). Health Technol Assess 16, iii-iv, 1–76.
44.Karow, A, Reimer, J, König, HH, et al. (2012) Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS Trial). J Clin Psychiatry 73, e402–e408.
45.Hastrup, LH, Kronborg, C, Bertelsen, M, et al. (2013) Cost-effectiveness of early intervention in first-episode psychosis: Economic evaluation of a randomised controlled trial (the OPUS study). Br J Psychiatry 202, 35–41.
46.Priebe, S, Savill, M, Wykes, T, et al. (2016) Clinical effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: A multicentre randomised controlled trial. Health Technol Assess 20, 1–100.
47.Rosenheck, R, Leslie, D, Sint, K, et al. (2016) Cost-effectiveness of comprehensive, integrated care for first episode psychosis in the NIMH RAISE Early Treatment Program. Schizophr Bull 42, 896–906.
48.Camacho, EM, Ntais, D, Jones, S, et al. (2017) Cost-effectiveness of structured group psychoeducation versus unstructured group support for bipolar disorder: Results from a multi-centre pragmatic randomised controlled trial. J Affect Disord 211, 27–36.
49.Lam, DH, McCrone, P, Wright, K, Kerr, N (2005) Cost-effectiveness of relapse-prevention cognitive therapy for bipolar disorder: 30-month study. Br J Psychiatry 186, 500–506.
50.Lenert, L, Sturley, AP, Rapaport, MH, et al. (2004) Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 71, 155–165.
51.Shiroiwa, T, Sung, Y-K, Fukuda, T, et al. (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: What is the threshold of cost effectiveness? Health Econ 19, 422–437.
52.Neumann, PJ, Cohen, JT, Weinstein, MC (2014) Updating cost-effectiveness — The curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371, 796–797.
53.Claxton, K, Martin, S, Soares, M, et al. (2015) Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 19, 1–503, v-vi.
54.Boutron, I, Tubach, F, Giraudeau, B, Ravaud, P (2004) Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials. J Clin Epidemiol 57, 543–550.
56.Nimdet, K, Chaiyakunapruk, N, Vichansavakul, K, Ngorsuraches, S (2015) A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: Does it justify CE threshold? PLoS One 10, e0122760.
57.Connell, J, O'Cathain, A, Brazier, J (2014) Measuring quality of life in mental health: Are we asking the right questions? Soc Sci Med Pergamon 120, 12–20.
58.Mulhern, B, Mukuria, C, Barkham, M, et al. (2014) Using generic preference-based measures in mental health: Psychometric validity of the EQ-5D and SF-6D. Br J Psychiatry 205, 236–243. http://www.ncbi.nlm.nih.gov/pubmed/24855127
59.Brazier, J (2010) Is the EQ-5D fit for purpose in mental health? Br J Psychiatry 197, 348–349.
60.Subramaniam, M, Abdin, E, Vaingankar, JA, et al. (2013) Impact of psychiatric disorders and chronic physical conditions on health-related quality of life: Singapore Mental Health Study. J Affect Disord 147, 325–330.
61.Konig, H-H, Born, A, Gunther, O, et al. (2010) Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with anxiety disorders. Health Qual Life Outcomes 8, 47.
62.Hayhurst, H, Palmer, S, Abbott, R, Johnson, T, Scott, J (2006) Measuring health-related quality of life in bipolar disorder: Relationship of the EuroQol (EQ-5D) to condition-specific measures. Qual Life Res 15, 1271–1280.
63.Reininghaus, U, Priebe, S (2012) Measuring patient-reported outcomes in psychosis: Conceptual and methodological review. Br J Psychiatry 201, 262–267.
64.Macpherson, R, Pesola, F, Leamy, M, et al. (2016) The relationship between clinical and recovery dimensions of outcome in mental health. Schizophr Res 175, 142–147.
65.Langer, AI, Schmidt, C, Mayol, R, et al. (2017) The effect of a mindfulness-based intervention in cognitive functions and psychological well-being applied as an early intervention in schizophrenia and high-risk mental state in a Chilean sample: Study protocol for a randomized controlled trial. Trials 18, 233.
66.Bell, CM, Urbach, DR, Ray, JG, et al. (2006) Bias in published cost effectiveness studies: Systematic review. BMJ 332, 699–703.
67.Thorn, JC, Noble, SM, Hollingworth, W (2013) Timely and complete publication of economic evaluations alongside randomized controlled trials. Pharmacoeconomics 31, 77–85.
68.Lal, S, Adair, CE (2014) E-mental health: A rapid review of the literature. Psychiatr Serv 65, 24–32.